Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine in Non-Metastatic Pancreatic Cancer
NCT04669197Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxychloroquine, nab-paclitaxel, gemcitabine, cisplatin in pancreatic adenocarcinoma (PDAC), sponsored by HonorHealth Research Institute. Started Dec 2020; status: completed.
02
Drugs
hydroxychloroquinenab-paclitaxelgemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04669197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669197.